Viemed Healthcare Inc VMD

Healthcare

Viemed Healthcare, Inc. through its subsidiaries, is a provider of home medical equipment (HME) and post-acute respiratory healthcare services in the United States. The Company’s service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counselling to patients in their homes using cutting edge technologies. The Company’s products and services include Home Medical Equipment, In-home sleep testing, and Healthcare staffing. Home Medical Equipment provides respiratory and other home medical equipment, including home ventilation, bi-level positive airway pressure (BiPAP) and continuous positive airway pressure (CPAP) devices, percussion vests, and other medical equipment. In-home sleep testing provides in home sleep apnea testing services. Healthcare staffing provides healthcare staffing and recruitment services. The Company provides home medical equipment services through its interest in East Alabama HomeMed, LLC (HomeMed).

NDAQ:VMD - Post by User

Viemed Healthcare Inc > Seeking Alpha story:

<< Previous

Bullboard Posts

Next >>

Comment by esiforon Aug 15, 2023 7:26pm

128 Views

Post# 35590077

RE:Seeking Alpha story:

Viemed Healthcare: Qualified Growth Company, HMP Transaction Accretive To Value

Aug. 15, 2023 3:36 PM ETViemed Healthcare, Inc. (VMD), VMD:CA

Zach Bristow

3.06K Followers

Summary

Viemed Healthcare's equity stock has consolidated by ~20% after a strong rally, but the company's economic outlook remains unchanged.
The acquisition of HMP has added potential value to VMD, expanding its geographical reach and bringing revenue synergies.
Viemed Healthcare's Q2 earnings showed strong growth, with sales up 31% YoY, and the company expects continued expansion in FY'23 and FY'24.
Net-net, reiterate buy.

Matteo Colombo

Investment updates

After rallying hard up the page for most of 2022 into Q2 FY'23, the equity stock of Viemed Healthcare, Inc. (NASDAQ:VMD) has consolidated by ~20%. Critically, the economic outlook of the company remains unchanged in my view, and completion of its HMP acquisition could add another $28mm to its top line almost immediately. It also continues its growth route via the contributions from its core business units, recycling and redeploying cash flows into additional inventory purchases to fuel demand.

There are multiple growth levers in VMD's arsenal in my opinion. In the last publication, I outlined the case for it to trade at $13—$17/share, and I've retained this target band following the latest investment findings. The recent pullback in market value offers a potentially exciting entry point, offering asymmetrical price returns ahead of the market's expectations (should my estimates come to fruition). Net-net, reiterate VMD as a buy.

Figure 1. VMD selling into a climax top where it broke the ascending channel shown. Following this technical setup it wasn't surprising to see an exhaustion of the rally.